278 related articles for article (PubMed ID: 23035648)
1. The National Institutes of Health criteria for classification and scoring of chronic graft versus host disease: long-term follow-up of a single center series.
Tecchio C; Mosna F; Andreini A; Paoli L; Di Bella R; de Sabata D; Sorio M; Pizzolo G; Benedetti F
Leuk Lymphoma; 2013 May; 54(5):1020-7. PubMed ID: 23035648
[TBL] [Abstract][Full Text] [Related]
2. National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.
Saillard C; Crocchiolo R; Furst S; El-Cheikh J; Castagna L; Signori A; Oudin C; Faucher C; Lemarie C; Chabannon C; Granata A; Blaise D
Leuk Lymphoma; 2014 May; 55(5):1106-12. PubMed ID: 23822538
[TBL] [Abstract][Full Text] [Related]
3. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.
Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D
Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of NIH consensus criteria for chronic graft-versus-host disease.
Cho BS; Min CK; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Kim CC
Leukemia; 2009 Jan; 23(1):78-84. PubMed ID: 18830253
[TBL] [Abstract][Full Text] [Related]
5. NIH-defined graft-versus-host disease and evidence for a potent graft-versus-leukemia effect in patients with acute lymphoblastic leukemia.
Terwey TH; Le Duc TM; Hemmati PG; le Coutre P; Nagy M; Martus P; Dörken B; Arnold R
Ann Oncol; 2013 May; 24(5):1363-70. PubMed ID: 23247660
[TBL] [Abstract][Full Text] [Related]
6. Graft-versus-tumor effect according to type of graft-versus-host disease defined by National Institutes of Health consensus criteria and associated outcomes.
Cho BS; Lee SE; Song HH; Lee JH; Yahng SA; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW
Biol Blood Marrow Transplant; 2012 Jul; 18(7):1136-43. PubMed ID: 22261380
[TBL] [Abstract][Full Text] [Related]
7. Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria.
Jagasia M; Giglia J; Chinratanalab W; Dixon S; Chen H; Frangoul H; Engelhardt B; Goodman S; Greer J; Kassim A; Morgan D; Ruffner K; Schuening F
Biol Blood Marrow Transplant; 2007 Oct; 13(10):1207-15. PubMed ID: 17889358
[TBL] [Abstract][Full Text] [Related]
8. Incidence and Outcome of Atypical Manifestations of Chronic Graft-versus-Host Disease: Results From a Retrospective Single-Center Analysis.
Doering J; Perl M; Weber D; Banas B; Schulz C; Hamer OW; Angstwurm K; Holler E; Herr W; Edinger M; Wolff D; Fante MA
Transplant Cell Ther; 2023 Dec; 29(12):772.e1-772.e10. PubMed ID: 37777112
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of subcategory and severity of chronic graft-versus-host disease evaluated by National Institutes of Health consensus criteria.
Sato T; Ichinohe T; Kanda J; Yamashita K; Kondo T; Ishikawa T; Uchiyama T; Takaori-Kondo A
Int J Hematol; 2011 Apr; 93(4):532-541. PubMed ID: 21465116
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study.
Grube M; Holler E; Weber D; Holler B; Herr W; Wolff D
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1781-1791. PubMed ID: 27343720
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria.
Ayuk F; Veit R; Zabelina T; Bussmann L; Christopeit M; Alchalby H; Wolschke C; Lellek H; Bacher U; Zander AR; Kröger N
Ann Hematol; 2015 Oct; 94(10):1727-32. PubMed ID: 26204824
[TBL] [Abstract][Full Text] [Related]
12. Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD.
Moon JH; Hamad N; Sohn SK; Uhm J; Alam N; Gupta V; Lipton JH; Messner HA; Seftel M; Kuruvilla J; Kim DD
Ann Hematol; 2017 May; 96(5):805-815. PubMed ID: 28214979
[TBL] [Abstract][Full Text] [Related]
13. Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria.
Cuvelier GDE; Nemecek ER; Wahlstrom JT; Kitko CL; Lewis VA; Schechter T; Jacobsohn DA; Harris AC; Pulsipher MA; Bittencourt H; Choi SW; Caywood EH; Kasow KA; Bhatia M; Oshrine BR; Flower A; Chaudhury S; Coulter D; Chewning JH; Joyce M; Savaşan S; Pawlowska AB; Megason GC; Mitchell D; Cheerva AC; Lawitschka A; West LJ; Pan B; Al Hamarneh YN; Halevy A; Schultz KR
Blood; 2019 Jul; 134(3):304-316. PubMed ID: 31043425
[TBL] [Abstract][Full Text] [Related]
14. Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study.
Kuzmina Z; Eder S; Böhm A; Pernicka E; Vormittag L; Kalhs P; Petkov V; Stary G; Nepp J; Knobler R; Just U; Krenn K; Worel N; Greinix HT
Leukemia; 2012 Apr; 26(4):746-56. PubMed ID: 21926960
[TBL] [Abstract][Full Text] [Related]
15. Reevaluation of the National Institutes of Health criteria for classification and scoring of chronic GVHD.
Kim DY; Lee JH; Lee JH; Kim SH; Lim SN; Kim SD; Choi Y; Lee YS; Kang YA; Kang SI; Seol M; Ryu SG; Lee KH
Bone Marrow Transplant; 2010 Jul; 45(7):1174-80. PubMed ID: 19915630
[TBL] [Abstract][Full Text] [Related]
16. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.
Baron F; Labopin M; Niederwieser D; Vigouroux S; Cornelissen JJ; Malm C; Vindelov LL; Blaise D; Janssen JJ; Petersen E; Socié G; Nagler A; Rocha V; Mohty M
Leukemia; 2012 Dec; 26(12):2462-8. PubMed ID: 22699419
[TBL] [Abstract][Full Text] [Related]
17. Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant.
Fraile P; Vazquez L; Caballero D; Garcia-Cosmes P; López L; San Miguel J; Tabernero JM
Eur J Haematol; 2013 Aug; 91(2):129-34. PubMed ID: 23710658
[TBL] [Abstract][Full Text] [Related]
18. New classification of chronic GVHD: added clarity from the consensus diagnoses.
Arora M; Nagaraj S; Witte J; DeFor TE; MacMillan M; Burns LJ; Weisdorf DJ
Bone Marrow Transplant; 2009 Jan; 43(2):149-53. PubMed ID: 18794869
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Cutaneous Disease Severity Estimates on Survival Outcomes in Patients With Chronic Graft-vs-Host Disease.
Baumrin E; Baker LX; Byrne M; Martin PJ; Flowers ME; Onstad L; El Jurdi N; Chen H; Beeghly-Fadiel A; Lee SJ; Tkaczyk ER
JAMA Dermatol; 2023 Apr; 159(4):393-402. PubMed ID: 36884224
[TBL] [Abstract][Full Text] [Related]
20. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
